Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus recommendation of “Buy” from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $49.91.

Several brokerages recently weighed in on DYN. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company.

Insider Activity

In related news, Director Jason P. Rhodes sold 782 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the sale, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders sold 21,071 shares of company stock worth $606,476 in the last quarter. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics in the 3rd quarter valued at approximately $36,000. US Bancorp DE raised its stake in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Dyne Therapeutics in the third quarter valued at $62,000. Finally, KBC Group NV raised its position in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Trading Down 3.0 %

Shares of DYN opened at $13.69 on Friday. The firm has a market capitalization of $1.39 billion, a PE ratio of -3.85 and a beta of 1.16. The stock’s 50 day moving average is $24.32 and its two-hundred day moving average is $32.77. Dyne Therapeutics has a twelve month low of $13.56 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.